Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Reuters NewMedia - Monday October 5, 1998
CEL-SCI, which develops treatments for diseases that attack the immune system, said in a statement that its HGP-30 vaccine had protected 78 percent of the mice that had been injected with the virus.
"These results provide evidence that HGP-30 may have worldwide applicability as an AIDS vaccine," it said.
Phase II testing began in the Netherlands last July and is expected to end in the first quarter of next year, a spokeswoman for the company said. CEL-SCI said in the statement that Dr. James Talmadge at the University of Nebraska Medical Center in Omaha, Neb., had injected the mice with the AIDS virus after giving them white blood cells from human volunteers, some of whom had been vaccinated with HGP-30.
The company said 78 percent of the mice given the blood from the vaccinated individuals, were protected from HIV infection. Of the mice receiving the non-vaccinated blood, only thirteen percent showed no evidence of infection.
Only after completing Phase III of clincial trials can a company seek permission from the Food and Drug Administration to sell a vaccine or other drug to the public.
981005
RE981004
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .